PURPOSE OF REVIEW: The treatment landscape of multiple myeloma is rapidly changing; however, despite improvement in patients' survival, it still remains a largely incurable disease. One hallmark of myeloma is substantial immune dysfunction leading to an increased infection rate and the inability of immune surveillance to detect neoplastic cells. Here, we critically analyze clinical approaches to harness the immune system to overcome this defect with a focus on antibody based and adoptive cellular therapies. RECENT FINDINGS: Clinical trials exploring these immunotherapies to treat myeloma are now well underway and show promising results. In relapsed myeloma, monoclonal antibodies directed against plasma cell antigens and immune checkpoints have already shown substantial efficacy. In parallel, trials of adoptive cellular therapy have exciting promise in myeloma, having induced dramatic responses in a handful of early study participants. Taken together, immunotherapeutic approaches hold enormous potential in the field of multiple myeloma and in the near future can be combined with or even replace the current standard of care.

Novel Immunotherapies for Multiple Myeloma

D'Agostino M
First
;
Boccadoro M;
2017-01-01

Abstract

PURPOSE OF REVIEW: The treatment landscape of multiple myeloma is rapidly changing; however, despite improvement in patients' survival, it still remains a largely incurable disease. One hallmark of myeloma is substantial immune dysfunction leading to an increased infection rate and the inability of immune surveillance to detect neoplastic cells. Here, we critically analyze clinical approaches to harness the immune system to overcome this defect with a focus on antibody based and adoptive cellular therapies. RECENT FINDINGS: Clinical trials exploring these immunotherapies to treat myeloma are now well underway and show promising results. In relapsed myeloma, monoclonal antibodies directed against plasma cell antigens and immune checkpoints have already shown substantial efficacy. In parallel, trials of adoptive cellular therapy have exciting promise in myeloma, having induced dramatic responses in a handful of early study participants. Taken together, immunotherapeutic approaches hold enormous potential in the field of multiple myeloma and in the near future can be combined with or even replace the current standard of care.
2017
12
4
344
357
https://link.springer.com/article/10.1007/s11899-017-0397-7
https://doi.org/10.1007/s11899-017-0397-7
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5693669/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5693669/pdf/nihms900667.pdf
BCMA; CAR T cell; CD38; Cellular therapy; Checkpoint blockade; PD-1; Animals; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Apoptosis; Humans; Immune System; Immunotherapy; Molecular Targeted Therapy; Multiple Myeloma; Hematology; Oncology; Cancer Research
D'Agostino M, Boccadoro M, Smith EL.
File in questo prodotto:
File Dimensione Formato  
[PUBLISHED Vsn.] D'Agostino et al - 2017 Curr Hematol Malig Rep.pdf

Accesso riservato

Descrizione: [Restricted access - Published vsn.] D'Agostino et al. Curr Hematol Malig Rep. 2017 Aug;12(4):344-357. doi: 10.1007/s11899-017-0397-7. © Springer Science+Business Media, LLC 2017. The published version is available at: https://link.springer.com/article/10.1007/s11899-017-0397-7 | https://doi.org/10.1007/s11899-017-0397-7 . The author version is available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5693669/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5693669/pdf/nihms900667.pdf
Tipo di file: PDF EDITORIALE
Dimensione 622.65 kB
Formato Adobe PDF
622.65 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1678928
Citazioni
  • ???jsp.display-item.citation.pmc??? 19
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 29
social impact